Table 1.
Dose‐level | hVEGF26‐104, μg | RFASE, mg |
---|---|---|
Dose‐level 1 a | 62.5 | 20 |
Dose‐level 2 | 125 | 20 |
Dose‐level 3A | 250 | 20 |
Dose‐level 3B | 250 | 40 |
Dose‐level 4 | 500 | 40 |
Dose‐level 5 | 1,000 | 40 |
The patients in dose‐level 1 received a first immunization with 20 mg RFASE alone to study the potential adverse effects of the adjuvant.
Abbreviation: RFASE, raffinose fatty acid sulphate ester.